Merck & Company, Inc. nyheder

MRKSeneste aktienyheder og analyser

Merck (MRK) Stock Sinks As Market Gains: Here's Why

Zacks·-29698935250 min. siden

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Business Wire·-29698720166 min. siden

Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer

MT Newswires·-29698580116 min. siden

Berenberg Adjusts Price Target on Merck to $127 From $125, Keeps Hold Rating

MT Newswires·-29698204466 min. siden

This Stock Market Is Full of Bargains, Our Roundtable Pros Say. 45 Picks for the Second Half.

Barrons.com·-29698903166 min. siden

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Zacks·-29696970266 min. siden

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires·-29698651450 min. siden

MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?

Zacks·-29695495166 min. siden

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?

Motley Fool·-29698291633 min. siden

JNJ Stock Keeps Climbing. Should You Climb On?

Trefis·-29698352716 min. siden

Nyheder leveret af Yahoo Finance. Reportly er ikke ansvarlig for indholdet af eksterne artikler. Ikke en handelsanbefaling.